Algo version: 0.98b
Oryzon Genomics SA is listed at the EURONEXT Exchange
Oryzon Genomics SA [ORY.MC]
EURONEXT Sector: Healthcare Industry:Biotechnology

Is Oryzon Genomics SA stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Oryzon Genomics SA 10 years ago, but if you had invested on Friday 22nd of November 2019 when the price was €2.70, you would have made a loss of €-1.122 per share or -41.56%

No, the average daily trading liquidity for Oryzon Genomics SA is €101 407 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

Oryzon Genomics SA has no real debt, which is good in periods of high inflation. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for Oryzon Genomics SA to be medium [0.7 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.